Literature DB >> 12907596

PML is required for homeodomain-interacting protein kinase 2 (HIPK2)-mediated p53 phosphorylation and cell cycle arrest but is dispensable for the formation of HIPK domains.

Andreas Möller1, Hüseyin Sirma, Thomas G Hofmann, Sven Rueffer, Elisabeth Klimczak, Wulf Dröge, Hans Will, M Lienhard Schmitz.   

Abstract

Here we demonstrate that endogenous human homeodomain-interacting protein kinase (HIPK) 2 and the highly homologous kinase HIPK3 are found in a novel subnuclear domain, the HIPK domains. These are distinct from other subnuclear structures such as Cajal bodies and nucleoli and show only a partial colocalization with promyelocytic leukemia (PML) nuclear bodies (PML-NBs). A kinase inactive HIPK2 point mutant is localized in the nucleoplasm. The occurrence of HIPK domains in PML-/- fibroblasts reveals their independence from the PML protein. HIPK2 can be almost completely recruited to PML-NBs by the PML isoform PML IV, but not by PML-III. PML IV-mediated recruitment of HIPK2 does not rely on its kinase function and also occurs in PML-/- fibroblasts, showing that this PML isoform is sufficient for recruitment of HIPK2. Whereas the architecture of HIPK domains is PML independent, HIPK2-mediated enhancement of p53-dependent transcription, p53 serine 46 phosphorylation and the antiproliferative function of HIPK2 strictly rely on the presence of PML.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12907596

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  51 in total

Review 1.  Posttranslational modification of p53: cooperative integrators of function.

Authors:  David W Meek; Carl W Anderson
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-10-28       Impact factor: 10.005

Review 2.  The DNA damage-induced cell death response: a roadmap to kill cancer cells.

Authors:  Sonja Matt; Thomas G Hofmann
Journal:  Cell Mol Life Sci       Date:  2016-01-20       Impact factor: 9.261

3.  Transcriptional regulation is affected by subnuclear targeting of reporter plasmids to PML nuclear bodies.

Authors:  Gregory J Block; Christopher H Eskiw; Graham Dellaire; David P Bazett-Jones
Journal:  Mol Cell Biol       Date:  2006-09-11       Impact factor: 4.272

4.  PML: An emerging tumor suppressor and a target with therapeutic potential.

Authors:  Erin L Reineke; Hung-Ying Kao
Journal:  Cancer Ther       Date:  2009-09-01

5.  PML activates transcription by protecting HIPK2 and p300 from SCFFbx3-mediated degradation.

Authors:  Yutaka Shima; Takito Shima; Tomoki Chiba; Tatsuro Irimura; Pier Paolo Pandolfi; Issay Kitabayashi
Journal:  Mol Cell Biol       Date:  2008-09-22       Impact factor: 4.272

Review 6.  The role of PML in the control of apoptotic cell fate: a new key player at ER-mitochondria sites.

Authors:  P Pinton; C Giorgi; P P Pandolfi
Journal:  Cell Death Differ       Date:  2011-04-08       Impact factor: 15.828

7.  Nuclear body movement is determined by chromatin accessibility and dynamics.

Authors:  Sabine M Görisch; Malte Wachsmuth; Carina Ittrich; Christian P Bacher; Karsten Rippe; Peter Lichter
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-26       Impact factor: 11.205

8.  PML IV/ARF interaction enhances p53 SUMO-1 conjugation, activation, and senescence.

Authors:  Lisa Ivanschitz; Yuki Takahashi; Florence Jollivet; Olivier Ayrault; Morgane Le Bras; Hugues de Thé
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-02       Impact factor: 11.205

9.  Overlapping roles for homeodomain-interacting protein kinases hipk1 and hipk2 in the mediation of cell growth in response to morphogenetic and genotoxic signals.

Authors:  Kyoichi Isono; Kazumi Nemoto; Yuanyuan Li; Yuki Takada; Rie Suzuki; Motoya Katsuki; Akira Nakagawara; Haruhiko Koseki
Journal:  Mol Cell Biol       Date:  2006-04       Impact factor: 4.272

Review 10.  Oncogene-induced senescence: an essential role for Runx.

Authors:  Anna Kilbey; Anne Terry; Ewan R Cameron; James C Neil
Journal:  Cell Cycle       Date:  2008-05-29       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.